Hedgehog Inhibition Promotes a Switch from Type II to Type I Cell Death Receptor Signaling in Cancer Cells

TRAIL is a promising therapeutic agent for human malignancies. TRAIL often requires mitochondrial dysfunction, referred to as the Type II death receptor pathway, to promote cytotoxicity. However, numerous malignant cells are TRAIL resistant due to inhibition of this mitochondrial pathway. Using chol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurita, Satoshi, Mott, Justin L., Cazanave, Sophie C., Fingas, Christian D., Guicciardi, Maria E., Bronk, Steve F., Roberts, Lewis R., Fernandez-Zapico, Martin E., Gores, Gregory J.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069071/
https://www.ncbi.nlm.nih.gov/pubmed/21483830
http://dx.doi.org/10.1371/journal.pone.0018330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069071/
https://www.ncbi.nlm.nih.gov/pubmed/21483830
http://dx.doi.org/10.1371/journal.pone.0018330

Ejemplares similares